Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HHAT | Q5VTY9 | 5/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | QDPR | P09417 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751291 | 0.85 | HHAT (0.38) | HHATNPC1RAB9APKMMAPK1 | |
| SCHEMBL19722754 | 0.84 | NPC1 (0.38) | HHATNPC1RAB9APKMMAPK1 | |
| SCHEMBL13194702 | 0.80 | NPC1 (0.35) | HHATNPC1RAB9ALMNAMAPK1 | |
| SCHEMBL15490061 | 0.80 | OPRM1 (0.38) | NPC1RAB9APKMMAPK1 | |
| SCHEMBL11433514 | 0.79 | KIF11 (0.59) | HHATKIF11NPC1RAB9ANOTUM | |
| SCHEMBL11604417 | 0.76 | LHCGR (0.48) | NPC1RAB9A | |
| SCHEMBL11606554 | 0.76 | GAA (0.41) | LMNA | |
| SCHEMBL11607640 | 0.74 | LHCGR (0.49) | NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL3307496 | 0.73 | HHAT (0.45) | HHATMAPK1NPSR1 | |
| SCHEMBL4751946 | 0.73 | HHAT (0.45) | HHATMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
| WO-2013074388-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | GPR119, GPR27, GCGR | HHAT 689/4885KIF11 4106/4885NPC1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.